<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18857" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Carbonic Anhydrase Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Aslam</surname>
            <given-names>Sanah</given-names>
          </name>
          <aff>Augusta University Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanah Aslam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18857.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Carbonic anhydrase inhibitors are a medication used to manage and treat glaucoma, idiopathic intracranial hypertension, altitude sickness, congestive heart failure, and epilepsy, among other diseases. Carbonic anhydrase inhibitors are considered part of the diuretic class of medications. This article reviews the indications, action, and contraindications for carbonic anhydrase inhibitors as valuable agents in treating glaucoma, idiopathic intracranial hypertension, and other disorders. This activity will highlight the mechanism of action, adverse event profile, and other key factors, e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions pertinent for members of the interprofessional healthcare team in the treatment of patients with glaucoma, idiopathic intracranial hypertension, and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of carbonic anhydrase inhibitors.</p></list-item><list-item><p>Describe the potential adverse effects of carbonic anhydrase inhibitors.</p></list-item><list-item><p>Review the appropriate monitoring necessary for carbonic anhydrase inhibitors.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to improve outcomes in patients receiving treatment with carbonic anhydrase inhibitors.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18857&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18857">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18857.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Carbonic anhydrase inhibitors are diuretic drugs with a wide variety of FDA-approved applications and have more recently been demonstrated to be beneficial for&#x000a0;several other&#x000a0;off-label clinical&#x000a0;uses.<xref ref-type="bibr" rid="article-18857.r1">[1]</xref><xref ref-type="bibr" rid="article-18857.r2">[2]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Elevated intraocular pressure (angle-closure and open-angle glaucoma)</p>
          </list-item>
          <list-item>
            <p>Pseudotumor cerebri</p>
          </list-item>
          <list-item>
            <p>Edema due to congestive heart failure</p>
          </list-item>
          <list-item>
            <p>Centrenchephalic epilepsies</p>
          </list-item>
          <list-item>
            <p>Altitude sickness prophylaxis<xref ref-type="bibr" rid="article-18857.r3">[3]</xref><xref ref-type="bibr" rid="article-18857.r4">[4]</xref><xref ref-type="bibr" rid="article-18857.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Examples of Non-FDA-Approved Indications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sleep apnea</p>
          </list-item>
          <list-item>
            <p>Cerebrospinal fluid leak</p>
          </list-item>
          <list-item>
            <p>Reversal of metabolic alkalosis in chronic obstructive pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Prevention of contrast-induced nephropathy</p>
          </list-item>
        </list>
        <p>In the kidneys, carbonic anhydrase inhibitors (CAIs) result in the inhibition of bicarbonate uptake by the proximal tubule, resulting in the alkalization of urine. In the eyes, CAIs are classically used in the management of glaucoma due to their ability to reduce the secretion of aqueous humor, thereby lowering the intraocular pressure. Furthermore, CAIs are used for chronic open-angle glaucoma and acute angle-closure glaucoma before surgery.<xref ref-type="bibr" rid="article-18857.r3">[3]</xref> Similarly, CAIs reduce cerebrospinal fluid production, allowing them to be useful in managing idiopathic intracranial hypertension. The effect of mild metabolic acidosis makes CAIs favorable for the prevention and management of acute mountain sickness, an illness that occurs due to conditions of hypoxia.<xref ref-type="bibr" rid="article-18857.r3">[3]</xref><xref ref-type="bibr" rid="article-18857.r6">[6]</xref><xref ref-type="bibr" rid="article-18857.r7">[7]</xref>&#x000a0;Urinary alkalinization occurs as a result of increased bicarbonate excretion. Carbonic anhydrase inhibitor acetazolamide may be used to alkalize urine to solubilize uric acid and cystine stones.</p>
        <p>The adverse effects&#x000a0;of CAIs&#x000a0;that researchers and patients have reported&#x000a0;include fatigue, vomiting, nausea, and abdominal pain. Stevens-Johnson syndrome is a rare side effect.<xref ref-type="bibr" rid="article-18857.r7">[7]</xref>&#x000a0;The alkalization of urine may promote the formation of calcium oxalate stones. Acetazolamide, dichlorphenamide, methazolamide, dorzolamide, and brinzolamide are used primarily to treat glaucoma. Zonisamide and ethoxzolamide are used as antiepileptic medications.<xref ref-type="bibr" rid="article-18857.r8">[8]</xref></p>
        <p>CAIs may be used topically, orally, or through the intravenous route. The use of these drugs requires caution and routine monitoring in patients with&#x000a0;decreased&#x000a0;kidney or liver function.&#x000a0;The dose ranges are different for glaucoma, altitude sickness, and diuresis, depending on the route of drug administration.&#x000a0;</p>
      </sec>
      <sec id="article-18857.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Carbonic anhydrase in the lumen of the proximal tubule of the kidney converts carbonic acid to water and carbon dioxide. Water and carbonic dioxide enter the intracellular space via diffusion. The intracellular carbonic anhydrase enzyme converts water and carbon dioxide back to carbonic acid, which dissociates into H+ and bicarbonate. By inhibition of the enzyme, CAI medications result in the inhibition of the resorption of bicarbonate by the tubular cells, leading to retention of bicarbonate in the tubular lumen. The overall effect is the alkalization of urine as there is greater bicarbonate in the urine, and the blood becomes more acidic, given the excretion of bicarbonate. The diuretic effect causes increased water excretion and a decrease in blood pressure. The resulting changes in acid-base balance make CAIs useful in treating altitude sickness by counteracting respiratory alkalosis due to hyperventilation.&#x000a0;</p>
        <p>In the eyes, carbonic anhydrase inhibitors reduce the production of aqueous humor by the epithelium of the ciliary body by reducing the production of bicarbonate ions and presumably reducing fluid flow. The reduction in aqueous humor production lowers the intraocular pressure, making these drugs favorable in patients with glaucoma.</p>
      </sec>
      <sec id="article-18857.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Carbonic anhydrase inhibitors may be administered&#x000a0;via topical, oral, or IV routes. Examples of carbonic inhibitor medications currently available are acetazolamide, methazolamide, dorzolamide, brinzolamide, diclofenamide, ethoxzolamide, and zonisamide.</p>
        <p>The carbonic anhydrase inhibitor medications used for glaucoma are divided into topical and systemic subgroups. Topical carbonic anhydrase inhibitors, including dorzolamide and brinzolamide, can reach the ciliary body through corneal penetration.&#x000a0;These medications may be used as monotherapy but are often used in combination with other glaucoma medications. Dorzolamide hydrochloride preparation is available as a 2% solution, and brinzolamide is available as a 1% suspension; the recommended dosage for medications is 1 drop in both eyes three times daily when used alone or twice daily when used with other glaucoma medications. Dorzolamide is also available in combination with timolol in a 2%/0.5% solution. Systemic carbonic inhibitors, such as acetazolamide, methazolamide, ethoxzolamide, and dichlorphenamide, are indicated when intraocular pressure cannot be reduced&#x000a0;via topical administration and in acute angle-closure glaucoma when vomiting may necessitate the parenteral route.<xref ref-type="bibr" rid="article-18857.r9">[9]</xref></p>
        <p>Acetazolamide is available in 125, 200, and 500 mg tablets.&#x000a0;Patients with glaucoma&#x000a0;may take nearly 250 mg to 1000 mg per day. The dose range is higher for&#x000a0;the treatment of&#x000a0;altitude sickness. The treatment of edema, epilepsy, and diuresis in congestive heart failure with a carbonic anhydrase inhibitor medication requires lower doses.<xref ref-type="bibr" rid="article-18857.r10">[10]</xref>&#x000a0;It is also available in IV form; the maximal effect through intravenous administration occurs as quickly as 20 minutes.&#x000a0;</p>
        <p>Methazolamide is available in 25 mg and 50 mg tablets. The recommended dosing of methazolamide for glaucoma is 50&#x000a0;to 100 mg twice daily (BID) or three times daily (TID), whereas dosing for altitude sickness is 150&#x000a0;to 200 mg once daily. Dichlorphenamide, used in the treatment of open-angle glaucoma as well as preoperative acute closed-angle glaucoma, is available as a 50 mg tablet by mouth.&#x000a0;</p>
        <p>Recommendations for patients taking carbonic anhydrase inhibitors include drinking water at the time of administration to avoid the formation of kidney stones due to increased urinary alkalinization.<xref ref-type="bibr" rid="article-18857.r11">[11]</xref></p>
      </sec>
      <sec id="article-18857.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Carbonic anhydrase inhibitors may have many adverse effects, including changes in taste, fatigue, abdominal pain, diarrhea, nausea, vomiting, blurred vision, tinnitus, paresthesia, and headache. Both oral and topical drugs are sulfonamide derivatives. Sulfonamide structure can cause allergic reactions such as rash, anaphylaxis, and in rare cases, Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).&#x000a0;Adverse effects of topical carbonic anhydrase inhibitors include burning, superficial punctate keratopathy, and local inflammatory reactions of the conjunctiva. A bitter aftertaste is a common effect reported by patients. Systemic carbonic anhydrase inhibitors correlate with increased side effects, such as those previously mentioned, and serious effects such as metabolic acidosis, hypokalemia, aplastic anemia, agranulocytosis, nephrolithiasis, and fulminant hepatic necrosis.<xref ref-type="bibr" rid="article-18857.r6">[6]</xref> The alkalinization of urine resulting from increased bicarbonate excretion may promote the development of calcium oxalate kidney stones.<xref ref-type="bibr" rid="article-18857.r10">[10]</xref><xref ref-type="bibr" rid="article-18857.r7">[7]</xref></p>
      </sec>
      <sec id="article-18857.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Due to the risk of fulminant hepatic necrosis, carbonic anhydrase inhibitors should not be used in patients with hepatic disease, such as cirrhosis or impaired hepatic function. Liver injury is a rare side effect, but there have been several case reports. The mechanism of hepatic injury is presumed to be due to cross-reactivity with sulfonamide reactions. The damage occurs days to weeks after medication administration. The severity of the hepatic injury ranges from elevations of serum enzymes in a mixed or hepatocellular pattern to acute fulminant liver failure.<xref ref-type="bibr" rid="article-18857.r10">[10]</xref></p>
        <p>Patients with hypersensitivity to sulfonamides should use carbonic anhydrase inhibitors with caution due to the risk of fatal anaphylactic shock.<xref ref-type="bibr" rid="article-18857.r10">[10]</xref>&#x000a0;Any patient with a history of a serious drug-induced rash should avoid this class of medications. Certain HLA genotypes, particularly HLA-B*5901, are strongly associated with methazolamide-induced SJS/TEN, warranting genetic screening as a useful predictor of SJS/TEN before initiating methazolamide in Korean and Japanese patients.<xref ref-type="bibr" rid="article-18857.r12">[12]</xref><xref ref-type="bibr" rid="article-18857.r13">[13]</xref></p>
        <p>Carbonic anhydrase inhibitors may cause electrolyte imbalances and are therefore not recommended in patients with hypokalemia, hyponatremia, metabolic acidosis, hyperchloremic acidosis, adrenal insufficiency, or marked renal impairment.&#x000a0;Drug interactions of carbonic anhydrase inhibitors have been reported using nonsteroidal anti-inflammatory drugs (NSAIDs), beta-blockers, oral contraceptives, antifungals, lithium, metformin, clopidogrel, diuretics, and antiepileptics.<xref ref-type="bibr" rid="article-18857.r8">[8]</xref>&#x000a0;Carbonic&#x000a0;anhydrase inhibitor causes alkalization of urine, which is&#x000a0;presumed to interact with the excretion of many medications.&#x000a0;</p>
      </sec>
      <sec id="article-18857.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Blood urea nitrogen to creatinine ratio, complete blood count, platelets, and electrolytes should be examined at baseline before initiating acetazolamide and methazolamide and monitored periodically. Potassium and sodium bicarbonate levels, in particular, should be monitored.</p>
        <p>A rare adverse effect of this drug is hepatotoxicity. Liver injury is precipitated by cross-reactivity of acetazolamide to sulfonamide reactions, indicated by elevation of liver enzymes days to weeks after the initiation of the drug. Monitoring liver enzymes may be necessary upon initiation of systemic carbonic anhydrase inhibitors.</p>
      </sec>
      <sec id="article-18857.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There have been reports of toxicity in a few cases in chronically receiving aspirin therapy and patients undergoing hemodialysis. Symptoms of toxicity are lethargy, confusion, fatigue, and incontinence. Salicylate may compete with acetazolamide plasma protein binding and inhibit renal clearance.<xref ref-type="bibr" rid="article-18857.r14">[14]</xref>&#x000a0;Similarly, patients on dialysis should avoid this class of drugs due to inhibited renal function and the risk of elevated serum concentrations.<xref ref-type="bibr" rid="article-18857.r15">[15]</xref> Symptoms of toxicity resolve a few days after discontinuing the medication. There is no reported antidote for carbonic anhydrase inhibitor toxicity.</p>
      </sec>
      <sec id="article-18857.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the risks of serious adverse effects such as toxicity, hepatic failure, and SJS/TEN, carbonic anhydrase inhibitors should be prescribed cautiously. It is essential for all interprofessional healthcare team members, including clinicians (MDs, DOs, NPs, and PAs), nurses, and pharmacists, to know the contraindications and recognize the side effects of these medications. Effective communication between the team and the patient is essential to reduce adverse effects. There is no antidote for carbonic anhydrase inhibitors; therefore, medication use in patients with impaired renal and liver function requires close monitoring. Nurses can participate in patient counseling and serve as a contact point for clinicians. Pharmacists should verify appropriate dosing based on indication, perform medication reconciliation to check for drug-drug interactions, and can also counsel the patient on dosing, administration, and potential adverse events. When prescribing carbonic anhydrase inhibitors, this interprofessional approach to care will drive improved outcomes and reduce potential adverse events.</p>
        <p>It is the job of the interprofessional healthcare team to ensure that the patient understands the difference in administration through oral or topical routes. In the setting of severe glaucoma, patients may be taking several topical and oral intraocular pressure-lowering drugs and should be careful to use the recommended dosages. Ophthalmic eye drop bottles with different cap colors may help avoid confusion and over administration. Many randomized-control trials and meta-analyses have confirmed the safety and efficacy of topical carbonic anhydrase inhibitors, such as dorzolamide and brinzolamide, combined with other glaucoma medications such as prostaglandin analogs or beta-blockers.<xref ref-type="bibr" rid="article-18857.r16">[16]</xref>&#x000a0;[Level 1]&#x000a0;</p>
      </sec>
      <sec id="article-18857.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18857&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18857">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18857/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18857">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18857.s11">
        <title>References</title>
        <ref id="article-18857.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kassamali</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sica</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide: a forgotten diuretic agent.</article-title>
            <source>Cardiol Rev</source>
            <year>2011</year>
            <season>Nov-Dec</season>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>276</fpage>
            <page-range>276-8</page-range>
            <pub-id pub-id-type="pmid">21983315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Farzam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abdullah</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <chapter-title>Acetazolamide</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>2</day>
            <pub-id pub-id-type="pmid">30335315</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Berkel</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Elefritz</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Evaluating off-label uses of acetazolamide.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2018</year>
            <month>Apr</month>
            <day>15</day>
            <volume>75</volume>
            <issue>8</issue>
            <fpage>524</fpage>
            <page-range>524-531</page-range>
            <pub-id pub-id-type="pmid">29626002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Assadi</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2006</year>
            <season>Mar-Apr</season>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>238</fpage>
            <page-range>238-42</page-range>
            <pub-id pub-id-type="pmid">16391986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Javaheri</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide improves central sleep apnea in heart failure: a double-blind, prospective study.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>15</day>
            <volume>173</volume>
            <issue>2</issue>
            <fpage>234</fpage>
            <page-range>234-7</page-range>
            <pub-id pub-id-type="pmid">16239622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leaf</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness.</article-title>
            <source>J Appl Physiol (1985)</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>4</issue>
            <fpage>1313</fpage>
            <page-range>1313-22</page-range>
            <pub-id pub-id-type="pmid">17023566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Her</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kil</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson syndrome induced by acetazolamide.</article-title>
            <source>J Dermatol</source>
            <year>2011</year>
            <month>Mar</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>272</fpage>
            <page-range>272-5</page-range>
            <pub-id pub-id-type="pmid">21342230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Supuran</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2016</year>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-31</page-range>
            <pub-id pub-id-type="pmid">26878088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Masini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Carta</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Scozzafava</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Supuran</surname>
                <given-names>CT</given-names>
              </name>
            </person-group>
            <article-title>Antiglaucoma carbonic anhydrase inhibitors: a patent review.</article-title>
            <source>Expert Opin Ther Pat</source>
            <year>2013</year>
            <volume>23</volume>
            <issue>6</issue>
            <fpage>705</fpage>
            <page-range>705-16</page-range>
            <pub-id pub-id-type="pmid">23627893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Carbonic Anhydrase Inhibitors</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>10</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31643975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghorai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pulya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Panda</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gayen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Structure-activity relationship of human carbonic anhydrase-II inhibitors: Detailed insight for future development as anti-glaucoma agents.</article-title>
            <source>Bioorg Chem</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>95</volume>
            <fpage>103557</fpage>
            <pub-id pub-id-type="pmid">31911296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tangamornsuksan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lohitnavy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.</article-title>
            <source>Pharmacogenomics J</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>286</fpage>
            <page-range>286-294</page-range>
            <pub-id pub-id-type="pmid">30242287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Jee</surname>
                <given-names>YK</given-names>
              </name>
            </person-group>
            <article-title>HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.</article-title>
            <source>Pharmacogenomics</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>879</fpage>
            <page-range>879-84</page-range>
            <pub-id pub-id-type="pmid">20504258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sweeney</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Chapron</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Brandt</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gomolin</surname>
                <given-names>IH</given-names>
              </name>
              <name>
                <surname>Feig</surname>
                <given-names>PU</given-names>
              </name>
              <name>
                <surname>Kramer</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1986</year>
            <month>Nov</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>518</fpage>
            <page-range>518-24</page-range>
            <pub-id pub-id-type="pmid">3769383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwenk</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>St Peter</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Meese</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Acetazolamide toxicity and pharmacokinetics in patients receiving hemodialysis.</article-title>
            <source>Pharmacotherapy</source>
            <year>1995</year>
            <season>Jul-Aug</season>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>522</fpage>
            <page-range>522-7</page-range>
            <pub-id pub-id-type="pmid">7479208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18857.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or &#x003b2;-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>679</fpage>
            <pub-id pub-id-type="pmid">31293419</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
